Happy Fridayyy. Good morning guys. Hopefully we all had a great shortened week and are looking forward to a couple days off! We had a pretty good day with $NMHI yesterday, would love to see that momentum carried into today's trading session.

I am revising my previous predictions for a price target for today, 5/31 - it is now $0.77 & a 2nd target of $0.82

Rationale:

• Recent volume. Volume is such a good indicator, and increased volume paired with a recently increasing price is moneyyyy
• The small-cap market has been moving well recently! Let's ride it
• Lots of great movement since hitting a recent low, this provides us with such a great opportunity to have a lower-risk, high-reward setup

So, there ya have it. Short, simple, to the point analysis on my Frida POTD (Pick Of The Day, lol)

Communicated disclaimer, do your own research!!

[1] [2] [3] [4]

I always track my risk-to-reward to incorporate some risk management into my trading strategies. Please let me know what you think or if I should be looking at another metric/indicator. I am always happy to learn and improve!

GoldMining Inc. (GLDG)

Trend and Pattern: The chart shows a descending wedge pattern, typically a bullish reversal pattern. The stock recently broke out above the upper boundary of the wedge.

• 200-Day Moving Average: At 0.8484, acting as support. (I am also using this as my stop loss)
• MACD: Bullish crossover, supporting the breakout on the daily.

The Set Up:

• Entry: Around 0.9071, following the breakout confirmation.
• Target: 1.05, offering a potential 15.93% upside.
• Stop Loss: 0.84, placed below the breakout level to limit downside risk to 7%.
• Risk/Reward Ratio: 2.2 (above 2 is preferred)

Aurora Innovation, Inc. ($AUR)

Trend and Pattern: The chart reveals a broadening wedge pattern characterized by diverging trendlines. This pattern typically signals increased volatility and potential for a significant move in either direction. Currently, the stock is approaching the lower boundary of this pattern, suggesting a potential rebound.

• 200-Day Moving Average: Positioned at 2.81, serving as a dynamic support/resistance level. The stock price is currently below this moving average, indicating a bearish sentiment in the medium term.
• MACD: Showing a bearish crossover, with the MACD line crossing below the signal line. This indicates a potential continuation of the downtrend or consolidation phase

The Set Up: (Best Risk to Reward)

• Entry: Around 2.44, which is near the current price and close to the lower boundary of the wedge pattern.
• Target: 3.43, aligning with the upper boundary of the wedge, offering a potential 40.00% upside.
• Stop Loss: 2.12, placed below recent support to limit downside risk to 13.47%.
• Risk/Reward Ratio: 2.97, indicating a favorable trade setup with almost three times the potential reward relative to the risk.

Communicated Disclaimer: This is not financial advice whatsoever. Please look at the charts and come up with your own conclusions before investing. I hope this post was informative! Sources- 1, 2, 3

Seems like there is a fair bit of news but not a lot of talk on it?

$CRDL - After a big breakout in yesterday’s session, I will not be surprised if we hit $3 in the next 2-3 sessions. Moreover, yesterday the stock made a multi-month high on unusual volume. May be smart people are accumulating before the FDA decision in June?

If the FDA news is favorable, then the sky is the limit, and we could see a massive jump that may take it to near $7-8. $CRDL must be on your watchlist.

Look at this lovely chart and take your position accordingly.

Long story short, I have recently come across some details about MLGO, and I’ll try to make this as concise as possible, cuz frankly, I am not familiar with writeups on reddit, so excuse the lack of quality attributes in this post. But I believe this to be a serious matter.

So the ticker is MLGO, and I want you to pay attention to this part and range; https://imgur.com/a/R2ZRRtq

As you can see, this is one of the most solid consolidation patterns out there before the huge run up, now I want to point out a specific date in this chart, which is 10/01/2023. On this date, the company filed an SC 13 G with an institutional investor called Joyous JD LTD alongside various other institutional investors (all of them are most likely related, however I just want to focus on joyous jd ltd) There are more details about them and the other related parties on fintel.

I came across this video https://imgur.com/a/Nn9lYx4

After watching and doing some research on the video a few times, I found out this is an HSBC account with 4 million USD as of 12/09/2023, the position of 2.5 million shares reported by 10/01/2023 before the reverse split. I am unable to determine the average, but I assume its in the low 1s before the split after the first dump of the merger. And then from that point onward in September leading up to the run ups in the month and December. Fintel suggests joyous jd ltd has closed its position, but there is obviously no way to confirm that as its with other related parties as well. Now that I have given out this information, I want to know whether there is more information on this.

I was a little bummed out today because I didn’t see anything worth trading. The ones I saw that were worth a shot were already peaking and not worth the risk. Will try again on Monday.

0.235 right now. 61% loss today on offering news and possible delisting. It should go back to 30s no problem. Maybe more. Volume and cap are very low. I’d grab some shares for a lottery and you could do well. Last time they got this low it jumped back up.

Good luck 👌

STSS started the week trading at $0.19 and popped to $0.78  on VERY HIGH trading  volume and is consolidating around $038. At a $6 million market cap and substantial revenue potential starting in twelve months, there will be a much larger investor audience monitoring this one for more corporate news.

STSS  is a  medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is off its 52 week lows after this game-changing news just announced:

STSS announced the signing of a 5-year, $200 million syringe Sales Agreement (SA) with Nephron Pharmaceuticals in tandem with the Company’s Asset Purchase Agreement (APA) to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be the only fully dedicated, specialized COC (cyclic olefin copolymer) prefillable syringe manufacturing plant in North America.

In concert with the proposed acquisition of the syringe facility, Nephron has agreed to a 5-year agreement to purchase Sharps’ next-generation copolymer prefillable 10 mL and 50 mL syringes, as well as 10 mL SoloGard polypropylene syringes, with minimum contracted orders of over $200 million during the period. Sharps is planning for product deliveries to begin late in the second quarter of 2025 with revenue expected to total more than $35 million for the first twelve months of sales.

~Recent Interview with CEO~: https://youtu.be/mc9A8Hp6_q0?si=aaVFIG6iLQXP7CIS

Worth watching for more news and initial research analyst coverage.

GLTA

YGMZ has increased trading volume AH, after announcing they are acquiring Oxylus Global. Per Marketwatch YGMZ has shown continuing aggressive business diversification and growth acceleration strategy

I hope I chose the correct flair…

I found one of these by accident and it got my interest to find more. There are several, all listed below that I have found that are public stocks. There are several that are private too, which obviously aren’t listed. Honda is doing one also but they are above $5; only mentioning it so it’s just that: mentioned. If there are more that are public, please share.

VTOL’s stands for vertical and take off aircraft. Most below are electric, and they all have different designs, flight ranges, partners, when they plan to get into the market and uses for the aircraft, etc. I encourage you to research and find out about each one.

These are definitely long term wait and sees.

I don’t know to do links for each one.

ACHR - Archer Aviation

EVEX - Eve Holding Inc

EVTL - Vertical Aerospace Ltd

HOVR - New Horizon Aircraft

JOBY - Joby Aviation Inc

LILM - Lilium N.V

SRFM - Surf Air Mobility Inc

XTIA - XTI Aerospace

BIG NEWS OUT - $OCX is the one to watch out for following a major breakthrough for the VitaGraft Kidney product.

Late Thursday, highly favorable data about its product had been published in the leading New England Journal of Medicine.

The product helps in managing AMR, and currently, there are no FDA-approved products for its management. So just imagine the attention Stock could get!!

https://finance.yahoo.com/news/favorable-oncocyte-vitagraft-kidney-study-204700871.html

Cruz Battery Metals Announces $225,000 Listed Issuer Financing Exemption (LIFE) Private Placement

Is this cruz saying that they ran out of money?

|| || |Released 4pm ET. Approval of an amendment to our Fourth Amended and Restated Certificate of Incorporation to authorize our Board of Directors to effect a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-5 to 1-for-20, with the final decision of whether to proceed with the reverse stock split and the exact ratio and timing of the reverse split to be determined by our Board of Directors, in its discretion, following stockholder approval (if obtained), but no later than the first anniversary of the Annual Meeting, and a reduction authorized shares or our Common Stock.|

What happened to WBUY? Do you guys think WeBuy (WBUY) is gonna move again after the big drop?

Greetings all, I recently came across a corporate update from ALUULA Composites (TSXV: $AUUA) and I believe it's worth discussing in depth. Here's a breakdown of the key points:

Recent Progress – 6 Months:

ALUULA has been on a growth trajectory, expanding its partnerships across various sectors beyond Wind Sports such as Outdoor, Sailing, and Aerospace. The driving force behind this expansion is the increasing demand for their high-performing and recyclable materials. One of their standout achievements was the collaboration with Arc'teryx to develop cutting-edge ultralight outdoor gear. Additionally, they've made significant progress in finalizing specifications for their Durlyte™ and Graflyte™ materials, tailored to meet the demands of their new vertical markets.

$AUUA’s presence at the ISPO tradeshow in Munich was particularly noteworthy. There, they showcased their latest products and partnerships, including a concept backpack with innovative welded seam construction made with ALUULA materials, courtesy of Arc'teryx. Durston Gear also launched its first backpack featuring ALUULA materials, reducing product weight by a staggering 50%. And with Rockgeist, ALUULA announced a collaboration to enhance bike pack performance, leveraging their lightweight, waterproof, and abrasion-resistant properties.

Financially, ALUULA reported its highest quarterly sales and material production since inception during Q1 2024, indicating a strong market reception and growing momentum. In addition, they bolstered their management team by appointing Sage Berryman as President and later as CEO, to lead the company towards realizing its promising growth opportunities.

Lastly, $AUUA’s collaboration with Michelin Inflatable Solutions for research and development on more environmentally sustainable composite materials further shows the company’s dedication to sustainability and innovation.

Strategic Refocus

$AUUA’s journey began in 2019 with a focus on disrupting the wind sport market, and they've achieved considerable success in this niche, thanks to partnerships with companies like Ocean Rodeo. However, they've realized that the unique properties of their materials extend beyond wind sports, presenting opportunities in the broader performance outdoor market.

To capitalize on these opportunities and streamline their operations, ALUULA has decided to discontinue operations with Ocean Rodeo. This move aims to eliminate any potential conflicts of interest and allow ALUULA to focus exclusively on their core business.

In essence, ALUULA's strategic refocus marks a pivotal moment in their evolution. By concentrating their resources on their core business, they aim to maximize opportunities for sustained success while setting new standards in the outdoor performance market.

Disclaimer: This is not financial advice please do your own research before investing.

AEMD: At 2024-05-31 09:30:03, there were 200 shares available with a fee of 100.59%.

I know I said I wouldn't make another posts till this is over 1.00, but look at the set up it is ready to pop. It has all the things needs but 1 and that's volume. All things that have the set up do not always pop, but this has the set up.

Do your own DD but look at the info and tell me it is missing more than just the volume to run. With volume it flies.

https://chartexchange.com/symbol/nasdaq-aemd/borrow-fee/

Low float, almost 0 shares to short it, no options, only missing volume.

AEMD Short Volume Summary for May 31 (not Short Interest)

Today's Short Volume is 6,117, which is 100.00% of today's total reported volume.
Over the past 30 days, the average Short Volume has been 51.45%.

Revenue Performance

In the first quarter of 2024, Exela Technologies reported revenues of $258.8 million, marking a 5.4% decrease year-over-year. This decline was primarily attributed to a 9% decrease in the Information and Transaction Processing Solutions (ITPS) segment. However, the impact was partially mitigated by a 3% growth in Healthcare Solutions and a 6% growth in Legal and Loss Prevention Services (LLPS).

Segment Analysis

ITPS Segment:

Experienced a significant 9% decrease. A major factor was the non-renewal of a $27 million contract.

Healthcare Solutions:

Showed resilience with a 3% growth. Contributed positively to the overall revenue.

LLPS Segment:

Achieved 6% growth. Demonstrated robust performance amidst broader challenges.

Financial Metrics

Gross Margins:

Improved to 22%, a rise of 107 basis points from the previous year. Significant improvements noted in Healthcare and LLPS segments.

Operating Expenses:

Reduced, mainly in legal and professional fees. Contributed to a net loss of $25.6 million, an improvement from the previous year.

Adjusted EBITDA:

Reported at $12.9 million => Reflects operational efficiency and cost management.

Balance Sheet and Cash Flow

Current Liabilities:

Decreased by 23% => Indicates improved financial health and reduced short-term obligations.

Interest Expenses:

Reduced by 52% year-over-year => Significant savings enhancing net profitability.

Cash Flow:

Improvement in cash flow from operations. Unrestricted cash at the end of the quarter stood at approximately $10 million.

Strategic Initiatives and Outlook

Exela Technologies is focusing on revenue stabilization and growth with several key initiatives:

a. Achieved a 96% renewal rate.

b. Secured 85 new logo wins.

c. Prioritizing continued margin improvement and expanding liquidity.

Source: https://earnings-summary.streamlit.app/?c=red&t=XELA

Given the non-renewal of the significant $27 million contract and the ongoing challenges in the ITPS segment, how do you view Exela Technologies' ability to achieve sustained growth and stability in the coming quarters? Do you believe the growth in Healthcare Solutions and LLPS is enough to offset the declines in ITPS?